Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial

BACKGROUND: The emergent outbreak of coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emphasized the requirement for therapeutic opportunities to overcome this pandemic. Ivermectin is an antiparasitic drug that has shown effectiveness agains...

Descripción completa

Detalles Bibliográficos
Autores principales: Manomaipiboon, Anan, Pholtawornkulchai, Kittisak, Poopipatpab, Sujaree, Suraamornkul, Swangjit, Maneerit, Jakravoot, Ruksakul, Wiroj, Phumisantiphong, Uraporn, Trakarnvanich, Thananda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412770/
https://www.ncbi.nlm.nih.gov/pubmed/36028897
http://dx.doi.org/10.1186/s13063-022-06649-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412770/
https://www.ncbi.nlm.nih.gov/pubmed/36028897
http://dx.doi.org/10.1186/s13063-022-06649-3

Ejemplares similares